GE HealthCare Technologies Inc. - GEHC STOCK NEWS

GE HealthCare (Nasdaq: GEHC) has launched CT-Navigation, enhancing its precision care strategy by providing clinicians with real-time, 3D CT imaging for improved guidance during interventional procedures. This innovative technology allows for safer needle guidance, reducing radiation exposure and procedure time while improving patient outcomes. CT-Navigation simplifies intervention planning and offers real-time navigation, thus minimizing variability across procedures. Developed by IMACTIS, CT-Navigation is now part of GE HealthCare's portfolio following a recent acquisition and has received FDA clearance and EU Medical Devices Regulation approval. The company anticipates expanding this technology to its image-guided therapy business soon, increasing its market reach and clinical applications.

GE HealthCare (NASDAQ: GEHC) is set to showcase its innovative digital healthcare solutions at the HIMSS Global Health Conference in Chicago from April 17-21, 2023. Key products include Viewpoint 6, a scalable ultrasound IT solution, and ReadySee, an asset management and network supervision tool enhancing device monitoring and cybersecurity. The Portrait Mobile monitoring solution allows for wireless patient monitoring, while the MUSE Ecosystem integrates patient-acquired ECGs into existing workflows. GE HealthCare aims to improve patient care outcomes through its technology while advancing personalized and connected healthcare. The company operates an $18.3 billion enterprise with over 50,000 employees, committed to enhancing healthcare efficiency and patient experience.

GE HealthCare (Nasdaq: GEHC) is set to announce its first quarter 2023 financial results before the market opens on April 25, 2023. A conference call and webcast will be held at 8:00 a.m. Eastern Time on the same day, accessible through their Investor Relations website. GE HealthCare, a leader in medical technology and digital solutions, aims to enhance healthcare efficiency and patient outcomes. The company operates with a workforce of 50,000 employees and reported revenues of $18.3 billion. For more details, visit GE HealthCare's website.

GE HealthCare (Nasdaq: GEHC) has entered a strategic agreement with Advantus Health Partners worth up to $760M over 10 years. This collaboration aims to provide comprehensive Healthcare Technology Management (HTM) services to Advantus' clients, enhancing medical equipment maintenance beyond the traditional break-fix model. The initiative focuses on improving quality care while reducing costs through advanced asset management and proactive monitoring. The HTM program will include services like equipment recalls management and real-time location tracking, ultimately aiming for more efficient healthcare outcomes.

GE HealthCare has completed Phase I subject recruitment for a novel manganese-based macrocyclic MRI contrast agent. Announced at the European Congress of Radiology in Vienna, this investigational agent offers a potential alternative to traditional gadolinium-based agents, addressing concerns about gadolinium retention in the body. The clinical trial, led by Hasse K. Zaré at Oslo University Hospital, aims to assess its safety and elimination profile. Manganese, being naturally occurring in the body, ensures efficient excretion, positioning this agent as a promising addition to GE HealthCare's portfolio in precision imaging.

GE HealthCare has granted SonoThera exclusive global commercial licensing rights for its Optison® and Sonazoid® microbubble products. These products will aid the development of SonoThera’s innovative ultrasound-guided, nonviral gene therapy platform. The technology aims to non-invasively deliver diverse nucleic acid payloads to various organs, addressing significant delivery challenges in gene therapy. SonoThera is currently in preclinical development, preparing for Phase 1 clinical trials. Terms of the licensing agreement were not disclosed, but the collaboration underscores a shared commitment to improving patient outcomes.

GE HealthCare (Nasdaq: GEHC) announces that President and CEO Peter Arduini, along with Vice President and CFO Helmut Zodl, will present at two investor conferences in March 2023.

• Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 12:30 pm ET in New York City.
• Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 am ET (virtual event).

Investors can access the events live on GE HealthCare’s Investor Relations website. GE HealthCare is a leading global innovator in medical technology and digital solutions, focused on improving patient care.

GE HealthCare has signed an agreement to acquire Caption Health, Inc., an AI healthcare leader focused on early disease detection via ultrasound. This acquisition, strategic for GE's $3 billion ultrasound business, introduces AI-guided imaging, making ultrasounds more accessible for healthcare professionals. The technology aims to improve heart failure detection, particularly in at-risk patients, ultimately enhancing patient outcomes and reducing hospitalization rates. The deal's financial terms are undisclosed, and GE plans to fund it using cash on hand.

GE HealthCare reported a strong performance for 4Q 2022, with revenues of $4.9 billion, up 8% year-over-year, and 13% organic revenue growth. Net income was $554 million compared to $564 million last year, while adjusted EBIT increased to $844 million from $827 million. The net income margin declined to 11.2% from 12.3%. Despite these challenges, the company reaffirmed 2023 guidance, anticipating organic revenue growth of 5% to 7% and adjusted EPS between $3.60 to $3.75. The CEO expressed confidence in future revenue and margin growth driven by innovation and market demand.